Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 67Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Sarcoma 6Ovarian Neoplasms 4Brain Neoplasms 4Neoplasms 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Leiomyosarcoma 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HER2-negative Metastatic Breast Cancer 1

Interventions

Trastuzumab 2liposomal doxorubicin 1eribulin 1Metformin 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER-2 Positive Breast Cancer × eribulin × Clear all
NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Vector Oncology

Phase 1/2 Terminated
12 enrolled 12 charts
Breast

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡